Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21721608 | 0.78 | PTGS2 (0.32) | KMT2APTGS2PTGS1 | |
| SCHEMBL21721532 | 0.77 | PTGS1 (0.31) | KMT2APTGS2PTGS1 | |
| SCHEMBL21721535 | 0.77 | PTGS1 (0.31) | KMT2APTGS2PTGS1 | |
| SCHEMBL25111545 | 0.74 | F2RL3 (0.31) | — | |
| SCHEMBL2732554 | 0.72 | KMT2A (0.56) | KMT2AAPEX1ALDH1A1LMNAGAA | |
| SCHEMBL5157927 | 0.70 | PDE2A (0.33) | PDE2APDE4DPDE3APDE10A | |
| SCHEMBL10227000 | 0.70 | KMT2A (0.54) | KMT2AAPEX1ALDH1A1LMNAGAA | |
| SCHEMBL662111 | 0.70 | KMT2A (0.54) | KMT2AAPEX1ALDH1A1LMNAGAA | |
| SCHEMBL21720559 | 0.70 | PTGS2 (0.32) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL16441754 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868737-B2 | Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | SHANGHAI JIA TAN PHARMATECH CO. LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129888-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/P13K INHIBITOR | MTOR, PIK3CA, PIK3CD | KMT2A 2270/4885APEX1 2655/4885ALDH1A1 1561/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | KMT2A 1648/4885APEX1 2673/4885ALDH1A1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.